Tetragenetics, Inc.

Douglas Kahn

William Don Harriman

Hans De Haard

Paul A Colussi

Ellen J Collarini

Theodore G Clark

Lore Mariën

Ashot Papoyan

Yelena Bisharyan

Janna Bednenko

Joanna Cardarelli

Bas Van Der Woning

Alka Agrawal

Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.

Anti-Kv1.3 antibodies, and methods of production and use thereof

Growing community of inventors

Boston, MA, United States of America

Douglas Kahn